Pulmatrix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulmatrix, Inc. on June 23, 2020. The report details corporate governance changes, specifically the departure of a director and the appointment of a new director to the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Director Departure: Steve Gillis, Ph.D., tendered his resignation from the Board and all committees, effective September 1, 2020. The resignation was not related to any disagreement with the Company.
- Director Appointment: Christopher Cabell was appointed as a Class I director and a member of the Compensation Committee.
- Compensation for New Director: Dr. Cabell received an award of 30,000 stock options (exercise price $1.95) and an annual retainer of $30,000, plus an additional $3,000 annual retainer for Compensation Committee service.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on operations, or specific risk factors. The document notes that a press release regarding the appointment was issued on June 26, 2020.
Key Facts for Investor Verification
- Verify the effective date of Steve Gillis's resignation (September 1, 2020).
- Confirm the vesting schedule for Christopher Cabell's 30,000 stock options (25% at one year, then monthly).
- Review the attached press release (Exhibit 99.1) for additional context on the Board's strategic direction.
- Check subsequent filings for the impact of these governance changes on the Compensation Committee's decisions.